D.A. Davidson & Co. Annovis Bio, Inc. Transaction History
D.A. Davidson & Co.
- $15.6 Billion
- Q4 2025
A detailed history of D.A. Davidson & Co. transactions in Annovis Bio, Inc. stock. As of the latest transaction made, D.A. Davidson & Co. holds 160,779 shares of ANVS stock, worth $371,399. This represents 0.0% of its overall portfolio holdings.
Number of Shares
160,779Holding current value
$371,399% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ANVS
# of Institutions
53Shares Held
2.44MCall Options Held
167KPut Options Held
97.2K-
Vanguard Group Inc Valley Forge, PA923KShares$2.13 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA218KShares$504,5520.0% of portfolio
-
Geode Capital Management, LLC Boston, MA184KShares$425,3950.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il174KShares$402,7360.0% of portfolio
-
Northern Trust Corp Chicago, IL121KShares$279,6480.0% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $18.9M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...